The research and development department of The Payvand Clinical and Specialty Laboratory is seeking to develop new strategies to optimize the process of molecular and specialized diagnostic tests. The main activity of this group is the acquisition of new technologies in Specialized Laboratory Sciences in order to optimize the process of diagnostic clinical tests and test analysis. Finding operational standard guidelines, high-level analytical skills, reusable techniques and development of molecular genetic are considered appropriate approaches in this department, and in order to achieve it, there is a close relationship with reputable universities, laboratories and science centers. In addition to completing the laboratory equipment and laboratory devices in the quality control laboratory, the Research And Development group of The Payvand Laboratory has published periodicals of scientific articles in valid journals based on the information obtained from different sections of the laboratory, as well as the absorption of potential proposals to help meet the educational and research needs of the country's scientific community. For example, the publication of two books titled "ICSH Guideline for Standardization of the Naming, Detection and Reporting of Blood Cells Morphology" and "The Latest Guideline to the Chronic Myeloid Leukemia Network (CML)" over the past year implies the dynamics of the research section.







Research Projects

- Evaluation of therapy response in Iranian CML patients according to ELN guideline.
-Characterizing of BCR-ABL kinase domain mutations in CML patients with imatinib resistance.
- CALR (Calreticulin) exon 9 mutation analysis by PCR in JAK2- and MPL-negative patients.
- Identification of N-myc amplification in neurobelastoma.
- Diagnosis of FIP1L1-PDGFRA fusion in differentiation of Hyper Eosinophilic Syndrome (HES) and Chronic Eosinophilic Leukemia (CEL).


Newly Released Publications

F Roodbari, B Poopak, F Sheikhsofla, M Ghadiani. Evaluation of frequency of kirsten rat sarcoma gene mutations in Iranian colorectal cancer. Tehran Univ Med J (TUMJ) 2016;74(6):392-9.

Evaluating the diagnostic value of braf – v600emutation detection in iranian patients with hairycell leukemia. URMIA MED J 2016: 26(10): 881-888.

B Poopak, S Taghdisi, M Heidari, P Fallah, G Khosravipour, N Safari, S abieipoor. CYP2C19polymorphisms and their importance in Clopidogrel antiplatelet therapy. Res Mol Med (RMM) 2016, 4(3): 23-31.

L Rejali, B Poopak, M Hasanzad, F Sheikhsofla, A S Varnoosfaderani, N Safari, S Rabieipoor. Characterizing of Four Common BCR-ABL Kinase Domain Mutations (T315I, Y253H, M351T and E255K) in Iranian Chronic Myelogenous Leukemia Patients with Imatinib Resistance. Iran J Cancer Preven.2015;8(3):e2334.

B Poopak, S Rabieipoor, N Safari, E Naraghi, F Sheikhsofla, G Khosravipoor. Identification of CYP2C9 and VKORC1 polymorphisms in Iranian patients who are under warfarin therapy. International Journal of Hematology-Oncology and Stem Cell Research. 2015. 9(4):185-192.


Add comment

Security code

Powered by 2014 - All Rights Reserved.